By vgreene, 11 May, 2020 Interleukin 1 Blockade With High dose Anakinra in Patients With COVID 19 Acute Respiratory Distress Syndrome and Hyperinflammation A Retrospective Cohort Study
By vgreene, 11 May, 2020 Study considerations: retrospective; small sample size; historical bias; selection bias; varied dosing regimens
By vgreene, 11 May, 2020 24% on high dose D/C due to ADRs; 14% HD pts vs 13% SOC pts developed bacteremia; 10% HD pts vs 31% SOC pts had incr LFTs; no rebound inflammation
By vgreene, 11 May, 2020 Respiratory fxn improved in 72% HD vs 50% SOC; 10% HD pts died vs 44% SOC; higher cumulative survival in HD (90% vs 56%), no difference in mech vent-free survival; HD assoc w/ CRP decr at day 21 vs no decr w/ SOC
By vgreene, 11 May, 2020 Retrospective cohort study; 52 hospitalized non-ICU pts w/ confirmed COVID-19, mod-severe ARDS, and hyperinflammation managed w/ non-invasive vent and SOC, incl HCQ and LPV/r; 29 pts (median age 62y) received high-dose (HD) anakinra 5 mg/kg IV bid until s
By vgreene, 11 May, 2020 Observational Study of Hydroxychloroquine in Hospitalized Patients With COVID 19
By vgreene, 11 May, 2020 Study considerations non randomized weighted propensity score model treatment bias HCQ pts were generally sicker missing data and inaccuracies in EHR
By vgreene, 11 May, 2020 Primary composite endpoint (intubation or death) rates higher w/ HCQ (32%) vs no HCQ (15%) in unadjusted analysis (HR 2.37, 95% CI 1.84 to 3.02); adjusted analysis showed no significant association btwn HCQ use and composite endpoint (HR 1.04, 95% CI 0.82